Pain intensity on and off levodopa in patients with Parkinson's disease.
Identifieur interne : 002646 ( Ncbi/Merge ); précédent : 002645; suivant : 002647Pain intensity on and off levodopa in patients with Parkinson's disease.
Auteurs : Angelika Nebe [Allemagne] ; Georg EbersbachSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Pain (drug therapy), Pain (etiology), Pain Measurement, Parkinson Disease (complications), Parkinson Disease (drug therapy), Questionnaires, Severity of Illness Index, Statistics, Nonparametric.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Pain, Parkinson Disease.
- etiology : Pain.
- Aged, Female, Humans, Male, Middle Aged, Pain Measurement, Questionnaires, Severity of Illness Index, Statistics, Nonparametric.
Abstract
Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication.
DOI: 10.1002/mds.22546
PubMed: 19412949
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D31
- to stream PubMed, to step Curation: 001D31
- to stream PubMed, to step Checkpoint: 001C67
Links to Exploration step
pubmed:19412949Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease.</title><author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorder Clinic, Beelitz-Heilstätten, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Movement Disorder Clinic, Beelitz-Heilstätten</wicri:regionArea><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion></affiliation></author><author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22546</idno><idno type="RBID">pubmed:19412949</idno><idno type="pmid">19412949</idno><idno type="wicri:Area/PubMed/Corpus">001D31</idno><idno type="wicri:Area/PubMed/Curation">001D31</idno><idno type="wicri:Area/PubMed/Checkpoint">001C67</idno><idno type="wicri:Area/Ncbi/Merge">002646</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pain intensity on and off levodopa in patients with Parkinson's disease.</title><author><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorder Clinic, Beelitz-Heilstätten, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Movement Disorder Clinic, Beelitz-Heilstätten</wicri:regionArea><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion><wicri:noRegion>Beelitz-Heilstätten</wicri:noRegion></affiliation></author><author><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Pain (drug therapy)</term><term>Pain (etiology)</term><term>Pain Measurement</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pain</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pain Measurement</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19412949</PMID><DateCreated><Year>2009</Year><Month>06</Month><Day>29</Day></DateCreated><DateCompleted><Year>2009</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Pain intensity on and off levodopa in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1233-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22546</ELocationID><Abstract><AbstractText>Pain is frequently reported by patients with Parkinson's disease (PD). In this study, intensity of pain as measured by a visual analogue scale (VAS) was assessed on and off levodopa in 15 patients with PD. All patients had motor fluctuations and suffered from pain of various types. Description of pain was assessed with the McGill pain questionnaire. Ratings for pain intensity on the VAS were increased during off period for all patients but one (P = 0.001). There was a correlation (P = 0.04) between changes in motor performance (Unified Parkinson's Disease Rating Scale part III) and pain intensity (VAS). Compared with a historical sample of subjects with different pain syndromes without PD, terms related to fear and punishment were used more frequently by patients with PD in this study. In two patients, pain was exclusively limited to the off period. The majority of subjects suffered from secondary pain possibly related to lumbar osteoarticular degeneration. Secondary pain was relieved but not completely abolished by levodopa. The results of this study suggest that aggravation of secondary pain should be considered as a part of the spectrum of nonmotor off symptoms. Analgesics should not be given as first line drugs when pain occurs or increases in off conditions, and pain can be significantly alleviated or abolished by adjustments of dopaminergic medication.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nebe</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Movement Disorder Clinic, Beelitz-Heilstätten, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebersbach</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010147">Pain Measurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22546</ArticleId><ArticleId IdType="pubmed">19412949</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Ebersbach, Georg" sort="Ebersbach, Georg" uniqKey="Ebersbach G" first="Georg" last="Ebersbach">Georg Ebersbach</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Nebe, Angelika" sort="Nebe, Angelika" uniqKey="Nebe A" first="Angelika" last="Nebe">Angelika Nebe</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002646 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002646 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19412949
|texte= Pain intensity on and off levodopa in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19412949" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |